Malaria Vaccine Receives European Patent |
|
|
|
|
Written by Scott Cosby
|
|
Thursday, 26 July 2007 |
|
Sinobiomed Incorporated has recently received exclusive rights to develop, manufacture and sell a malaria vaccine.
The vaccine will be developed through Sinobiomed's subsidiary, Shanghai Wanxing Bio-pharmaceuticals.
Sinobiomed's malaria vaccine (PfCP2.9) targets the world's most deadly malaria parasite (Plasmodium falciparum) at its most destructive stage.
In the recently completed Phase I Clinical Trial, PfCP2.9 showed greater immunity and fewer adverse reactions. Phase II Clinical Trial will be conducted in China's Yunnan Province and in Southeast Asia.
Tags:
Click to add your tags...,
| Comments () >> |
 |
| Write comment |
You must be logged in to a comment. Please register if you do not have an account yet. |
 |
Contact
